Business Wire

1. Tremont AI Emerges From Stealth To Bring Multimodal AI To Preclinical Drug Safety 9/29/2026

   Tremont AI, a biomedical AI company focused on preclinical drug safety, today emerged from stealth. The company is developing multimodal foundation models and AI agents to help scientists analyze and interpret evidence across preclinical safety studies.

2. Bruker Advances Functional Proteomics With Novel timsUltra AIP And timsOmni Workflows For Drug Discovery & Development And Disease Biology Research 9/28/2026

   At the Human Proteome Organization World Congress 2026, Bruker Corporation today announced unique new timsUltra AIP and timsOmni workflows for deeper protein-sequence coverage, targeted validation, mobility-resolved glycopeptide characterization, structural proteomics, and oligonucleotide analysis.

3. Mission Bio Showcases Tapestri Across Drug Discovery And Clinical Development At World CDx Summit 9/28/2026

   Mission Bio, the single-cell multiomics leader, today announced that Merck & Co. and Incyte will each present new data generated using Mission Bio’s Assay Services and Tapestri Platform at the 16th World Clinical Biomarkers & Companion Diagnostics Summit (World CDx), alongside a third presentation from Mission Bio featuring new clinical data in acute myeloid leukemia.

4. Commercial Demand For Microgravity Drug Discovery Accelerates As Exobiosphere And Voyager Add Two Missions To The ISS 9/24/2026

   Voyager Technologies and Exobiosphere today announced two additional research campaigns aboard the International Space Station, expanding an agreement that is turning commercial biotech research in microgravity into a recurring, schedulable service rather than a one-off opportunity.

5. Iambic Launches Enchant v3 – Molecular Superintelligence Designed To Advance End-To-End Drug Discovery & Development 9/21/2026

   Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven platform, today unveiled Enchant v3, the next generation of its multimodal transformer model built to advance end-to-end drug discovery and development.

6. Niagen Bioscience Engages Veteran Pharmaceutical Executives And Biotechnology Experts To Support Drug Development Program And Strategic Business Growth 9/17/2026

   Niagen Bioscience, Inc., the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces today that its wholly owned subsidiary, NAD Pharmaceuticals Corp., has engaged Red Sky Partners, a life sciences strategic advisory firm, to support the advancement of NB4168, the Company’s small molecule investigational drug candidate, targeting rare genetic diseases and aging-related disorders.

7. Twist Bioscience Joins Lilly Tunelab To Advance Antibody Drug Discovery 9/16/2026

   Twist Bioscience Corporation, a mid-cap growth and value biotech company, today announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly).

8. Emulate Enters Final Stage Of FDA ISTAND Program For Human Liver-Chip With Submission Of Qualification Package Covering Both Zoë And AVA Organ-Chip Platforms 9/9/2026

   Emulate, Inc., the leading provider of next-generation Organ-on-a-Chip technology, today announced it has submitted its FDA Innovative Science and Technology Approaches for New Drugs (ISTAND) full qualification package (FQP) for its Human Liver-Chip, advancing the company's efforts to establish Organ-on-a-Chip technology as a qualified Drug Development Tool (DDT) for drug-induced liver injury (DILI) assessment.

9. Revvity To Acquire Human Cell Design To Advance Human-Relevant Cell Models For Metabolic Disease Drug Discovery 9/9/2026

   Revvity, Inc. today announced it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases.

10. BenchSci Announces Two-Year Enterprise Agreement With Argenx To Advance AI-Driven Preclinical Drug Discovery 9/2/2026

    BenchSci, a leading provider of AI software for biopharma research and development, today announced a two-year enterprise agreement with argenx, a global immunology innovation company, to deploy EMET, BenchSci's agentic research environment for preclinical drug discovery, within the organization.